Biogennix bone grafting product cleared for expanded spine indication — 3 insights

Osteobiologics company Biogennix received FDA clearance March 5 for an expanded indication of its Agilon moldable bone grafting product.

Advertisement

Three insights:

1. Agilon is now cleared for use in posterolateral spine procedures when mixed with autograft.

2. The product features a high purity, type 1 fibrillar bovine collagen, which offers a site for cell attachment, migration, proliferation and differentiation.

3. The Irvine, Calif.-based company is accelerating national distribution of Agilon, which is available in three different sizes.

More articles on devices:
Rothman Orthopaedics surgeon to lead orthopedic oncology program
New Southeastern Spine Institute moves closer to completion
Kevin Lobo’s 8+ years as Stryker CEO: Leading 20+ acquisitions, boosting robotics & more

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.